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To test the potential of a multigene DNA vaccine against lentivirus infection, we generated a defective mutant
provirus of feline immunodeficiency virus (FIV) with an in-frame deletion in pol (FIVDRT). In a first exper-
iment, FIVDRT DNA was administered intramuscularly to 10 animals, half of which also received feline gam-
ma interferon (IFN-g) DNA. The DNA was administered in four 100-mg doses at 0, 10, and 23 weeks. Immu-
nization with FIVDRT elicited cytotoxic T-cell (CTL) responses to FIV Gag and Env in the absence of a
serological response. After challenge with homologous virus at week 26, all 10 of the control animals became sero-
positive and viremic but 4 of the 10 vaccinates remained seronegative and virus free. Furthermore, quantitative
virus isolation and quantitative PCR analysis of viral DNA in peripheral blood mononuclear cells revealed
significantly lower virus loads in the FIVDRT vaccinates than in the controls. Immunization with FIVDRT in
conjunction with IFN-g gave the highest proportion of protected cats, with only two of five vaccinates showing
evidence of infection following challenge. In a second experiment involving two groups (FIVDRT plus IFN-g
and IFN-g alone), the immunization schedule was reduced to 0, 4, and 8 weeks. Once again, CTL responses
were seen prior to challenge in the absence of detectable antibodies. Two of five cats receiving the proviral DNA
vaccine were protected against infection, with an overall reduction in virus load compared to the five infected
controls. These findings demonstrate that DNA vaccination can elicit protection against lentivirus infection in
the absence of a serological response and suggest the need to reconsider efficacy criteria for lentivirus vaccines.
The continued spread of human immunodeficiency virus
(HIV) worldwide makes the development of an effective vac-
cine an urgent priority for world health. However, HIV and its
animal lentivirus counterparts present formidable challenges
for vaccine development because they cause persistent infec-
tion and induce disease despite a vigorous host immune re-
sponse (8). Among the available animal analogs of HIV, feline
immunodeficiency virus (FIV) has unique value as a wide-
spread naturally occurring infectious agent in its natural host
(45). Conventional approaches to vaccine development have
been pursued extensively for FIV and simian immunodefi-
ciency virus (SIV) but have yielded only qualified successes.
Whole inactivated virus vaccines have proved effective in the
FIV model, and protection is virus specific (48) but limited to
the homologous virus and may depend on a fortuitous vaccine
strain of virus which elicits strong neutralizing-antibody re-
sponses (16). Subunit vaccines based on purified or recombi-
nant Env glycoproteins have given some evidence of protection
against HIV in a small number of chimpanzees, but similar SIV
or FIV vaccines have led at best to reduced virus loads after
challenge and in some instances to enhancement of infection
(17, 22, 40). More robust resistance has been observed to SIV
after infection with attenuated strains lacking regulatory genes
such as nef (6), but safety fears make the use of this approach
in humans controversial (3, 46).
DNA-mediated immunization has emerged recently as a
promising alternative approach to the development of viral
vaccines, with protective immunity against viral infections such
as avian influenza (33), Newcastle disease (36), and Aujeszky’s
disease (13), as well as a wide range of nonviral pathogens
(reviewed in reference 42), being generated following in vivo
administration of naked DNA to muscle or skin. Given that
antiretroviral therapy is unlikely to be economically viable in
developing countries, a further attraction of DNA-mediated
immunization is the prospect of stable and affordable vaccines.
Several HIV-1 DNA constructs induce immune responses in
mice and primates (25, 38, 43), and forthcoming phase I trials
will assess the safety and immunogenicity of HIV-1 env DNA
in human subjects. Encouraging evidence for the use of DNA
vaccines was described recently when an HIV-1 DNA vaccine
containing env, rev, and gag/pol induced protective immunity in
the chimpanzee model (4). However, since HIV-1 is apatho-
genic in the chimpanzee model system, the question arises
whether similar approaches will be effective in inducing pro-
tection against lentivirus infection in the natural host species
that are susceptible to virus-induced disease, such as FIV in the
domestic cat.
In this study, we generated an FIV DNA vaccine construct
based on a replication-defective but essentially full-length pro-
viral genome which should express both structural and regula-
tory proteins in vivo. We investigated the efficacy of this FIV
DNA vaccine and demonstrated that a significant proportion
of the cats vaccinated with this DNA were protected from
subsequent challenge with the homologous virus. Further-
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more, the protective effect was retained in a second trial in-
volving a much shorter immunization schedule. This study pro-
vides the first evidence that DNA-mediated immunization can
prevent lentivirus infection in its natural host species.
MATERIALS AND METHODS
Cells and viruses. Cell culture media and supplements were obtained from
Life Technologies Inc., Paisley, United Kingdom. Crandell feline kidney (CrFK)
cells (5) were maintained in Dulbecco’s modification of minimal essential me-
dium Eagle supplemented with 10% heat-inactivated fetal bovine serum, 2 mM
glutamine, 0.11 mg of sodium pyruvate per ml, 100 mg of streptomycin per ml,
and 100 IU of penicillin per ml. MYA-1 cells (27) were maintained in RPMI 1640
medium supplemented with 10% heat-inactivated fetal bovine serum, 2 mM
glutamine, 100 IU of penicillin per ml, 100 mg of streptomycin per ml, 5 3 1025
M 2-mercaptoethanol (complete RPMI 1640 medium), and 2% culture super-
natant from the Ltk2IL2.23 cell line, a murine cell line stably transfected with the
human interleukin-2 (IL-2) gene and which produces high levels of human IL-2
(addition of 2% supernatant was found to be equivalent to addition of approx-
imately 100 IU of recombinant human IL-2). The Ltk2IL2.23 cell line was a kind
gift of M. Hattori, University of Tokyo. The FIV-PET challenge virus was
prepared as described previously (32) by transfection of the murine fibroblast cell
line NIH 3T3 with the F14 molecular clone of FIV-PET (28) and recovery into
the IL-2-dependent feline T-cell line Q201 (44).
Preparation of DNA immunogens. The reverse transcriptase (RT) deletion
mutant FIVDRT was prepared from the F-14 molecular clone of FIV-PET (28).
Cloning and characterization of feline gamma interferon (IFN-g) have been
described previously (1). For use as an adjuvant gene, the IFN-g cDNA was
subcloned into the pRC-RSV vector (Invitrogen B.V., De Schelp, The Nether-
lands) as a HindIII-NotI fragment.
Plasmid DNAs were purified by cesium chloride-ethidium bromide gradient
centrifugation followed by butanol extraction and ethanol precipitation. Follow-
ing resuspension in 10 mM Tris plus 1 mM EDTA, the plasmids were dialyzed
extensively against phosphate-buffered saline (PBS). Endotoxin levels were
quantified commercially by Q1 Biotech, Glasgow, United Kingdom, by the Limu-
lus amebocyte lysate technique and were found to be ,5 EU/ml.
DNA immunization and virus challenge. Kittens (12 weeks old) were random-
ized into groups of five for immunization. DNA was administered at four sites in
the gastrocnemius and quadriceps muscles (100 mg of each DNA in a total of 200
ml of PBS at each site). The cats were challenged with the homologous F-14
molecular clone of the FIV-PET isolate that had been subjected to titer deter-
mination by intraperitoneal inoculation of age-matched cats to calculate the 50%
infectious dose.
Detection of FIV-specific CTL. Lymphocytes were collected from peripheral
blood as described previously (10) and assayed directly for cytotoxic T-lympho-
cyte (CTL) activity. Target cells were autologous or allogeneic skin fibroblasts
derived from biopsy material collected prior to vaccination (9). The target cells
were labelled with 51Cr and infected with recombinant vaccinia viruses express-
ing FIV Gag (10) or Env (41) or wild-type vaccinia virus as a control. Effector
cells (.99% viable) were added at an effector-to-target-cell (E/T) ratio of 50:1,
and lytic activity was measured by monitoring isotope release as described pre-
viously (10).
Serological tests. Plasma samples were tested for the presence of anti-FIV
antibodies by immunoblot analysis as described previously (19). Peptide-based
enzyme-linked immunosorbent assays (ELISA) were used to determine titers of
antibodies recognizing an immunodominant epitope in the transmembrane gly-
coprotein (TM; CNQNQFFCK) (12, 30) by methods described previously (2,
39). Assays for virus-neutralizing antibodies were performed, by a method de-
scribed previously (29), on plasma samples taken on the day of challenge.
Immunoblotting. CrFK cells were transfected with the F-14 molecular clone,
the FIVDRT construct, or no DNA (mock transfected) by using LipofectAMINE
(Life Technologies) as specified by the manufacturer. The medium was changed
24 h posttransfection, and supernatants from the transfected cells were harvested
48 h later. These supernatants were clarified by centrifugation at 10,000 3 g for
10 min before virions were pelleted by ultracentrifugation at 200,000 3 g for 1 h.
The virions thus purified from 1 ml of culture fluid were analyzed by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblotting as de-
scribed elsewhere (19). Monoclonal antibody 43/1B9, recognizing FIV p24 (kind-
ly provided by N. Pedersen), was used for immunoblotting.
Isolation of FIV. On the day of challenge and at intervals of 3 weeks thereafter,
peripheral blood mononuclear cells (PBMC) were isolated from heparinized
venous peripheral blood by centrifugation over Ficoll-Hypaque (Pharmacia LKB
Biotechnology Inc., Piscataway, N.J.) and then either cultured directly or cocul-
tured with the IL-2-dependent feline T-cell line MYA-1 (27) in complete RPMI
1640 medium supplemented with 2% culture supernatant from the Ltk2IL2.23
cell line. Cultures were tested for the production of FIV p24 by ELISA (FIV
antigen test kit; IDEXX Laboratories, Portland, Maine) and were maintained for
21 days before being scored as negative.
Quantitative virus isolation. The infectious virus burden was measured 7 and
12 weeks after challenge. PBMC were isolated as described above, and decreas-
ing numbers of cells (2 3 106, 2 3 105, 2 3 104, 2 3 103, 2 3 102, 20, 2, or 0.2
cells) were cocultivated, in duplicate, in 48-well plates with 106 MYA-1 cells in a
total volume of 1.5 ml of complete RPMI medium. Samples of culture superna-
tant were tested on day 14 for the presence of FIV p24 by ELISA.
Statistical analyses. The proportions of infected cats in the four groups of cats
were compared by Fisher’s exact test. The statistical modelling of the initial
number of infected cells per 2 3 106 PBMC for each cat followed the classic
dilution assay analysis (26). For the first trial, the maximum-likelihood estimates
of the initial concentrations of infected cells were compared among the four
groups by a one-way analysis of variance. These estimates were log transformed,
after addition of a constant of 1, to better meet the “normality with equal
variance” assumptions. Pairwise contrasts between groups were analyzed by two
sample t tests. Groups 1 (FIVDRT) and 2 (FIVDRT plus IFN-g) were then
aggregated and compared with the two control groups via a two-sample t test.
These analyses were performed for each of the two periods separately, ignoring
the repeated-measures aspect. The P values cited for the two-sample t tests are
adjusted for multiple comparisons via permutation and should be regarded as
descriptive, reflecting the exploratory nature of the analyses. For the second trial,
similar methods were applied to compare estimates of the initial concentrations
of infected cells in the two groups of cats.
Proviral load measurement. DNA was prepared from PBMC and tested for
the presence of FIV sequences by quantitative nested PCR with primers from the
env gene as described previously (32). Duplicate assays were performed with pol
primers (outer, GAAGATAAATTACAGGAAGAACC and CTCATTTCCTG
GAATACCTTTA; inner, GATGGGTTATGAATTACATCCA and GGACCC
AATCTATAAATTGC) under identical conditions. Each PCR was validated
with a set of dilutions of DNA derived from the FL4 cell line (47). Assays were
performed on aliquots of DNA prepared from PBMC at inputs of 250, 500, and
1,000 ng. Positive scores were assigned to denote the amplification in one or
more aliquots.
RESULTS
Generation of a replication-defective FIV vaccine construct
(FIVDRT). The F-14 molecular clone of FIV-PET has previ-
ously been shown to be infectious for cats following intramus-
cular injection of plasmid DNA (32). To render the FIV pro-
virus noninfectious while leaving as much as possible of the
coding potential intact, deletions were generated around a
PacI restriction site located within the RT coding sequence at
the hinge between the RT and RNase H domains (28). From
a library of clones generated by sequential PacI and Bal 31
digestion and religation, we selected a recombinant which had
sustained a 33-codon deletion. The precise boundaries of this
deletion are shown in Fig. 1 below a partial restriction map of
the F-14 proviral clone (28). Characterization of this deletion
mutant has shown that it is completely defective with respect to
virion infectivity and RT activity. However, transfection studies
FIG. 1. Partial restriction map of the FIV-PET F-14 molecular clone which
was received as a subclone in plasmid pGEM7Zf1. The location of the major
open reading frames (stippled boxes) and long terminal repeats (solid boxes) is
shown underneath. The unique PacI site (P) used in mutagenesis and an adjacent
XbaI site (X) are boxed in the diagram and underlined in the primary sequence
below. The extent of the Bal 31-generated deletion in FIVDRT is indicated by
dots above the sequence. Numbering is relative to the published sequence (Gen-
Bank accession no. M25381 [28]). Other restriction sites: S, SacI; R, EcoRI; N,
NcoI; K, KpnI; B, BglII.
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showed that FIVDRT is essentially normal in Env-mediated
cell fusion and viral antigen release (data not shown). As
shown in Fig. 2, CrFK cells transfected with FIVDRT and the
parental F-14 clone release similar levels of viral proteins. The
FIVDRT-derived virions showed a consistent reduction in the
extent of Gag protein processing, suggesting some impairment
of Gag-Pol precursor transport or function, but since authentic
processing was clearly occurring, this proviral construct was
adopted as the basis of the FIVDRT DNA vaccine.
DNA vaccination with FIVDRT induces a virus-specific CTL
response. In the first vaccine trial of FIVDRT, three groups
of five cats were immunized with DNA comprising either
FIVDRT, FIVDRT in conjunction with IFN-g, or IFN-g alone.
A fourth control group received no DNA. A line diagram
depicting the schedule is shown in Fig. 3. Virus-specific CTL
responses were first detected in unstimulated peripheral blood
three weeks following the first immunization. Gag- and Env-
specific CTL responses were observed in all cats immunized
with FIVDRT (Fig. 4a), although the magnitude of the re-
sponse varied between individual animals, as might be ex-
pected given the outbred nature of the study population, with
higher levels of 51Cr release observed in cats A481 to A483
than in cats A484 and A485. However, in all cats the observed
lysis exceeded 10% at an E/T ratio of 50:1. The CTL activity
was not observed when allogeneic target cells were used in the
assay, suggesting that the observed activity was major histo-
compatibility complex restricted. There was also no recogni-
tion of autologous target cells infected with wild-type vaccinia
virus, confirming the specificity of the response.
Coimmunization with FIVDRT and IFN-g DNA also elic-
ited FIV Gag- and Env-specific CTL responses in the unstimu-
lated PBMC of all cats, and in some of these animals higher
levels of 51Cr release were detected than in cats inoculated
with FIVDRT alone (Fig. 4b). However, these responses were
not entirely major histocompatibility complex restricted since
lysis of allogeneic target cells was also observed. The nonspe-
cific nature of the cytolytic responses observed following IFN-g
DNA immunization was also indicated by the recognition of
autologous target cells infected with wild-type vaccinia virus.
Furthermore, immunization with IFN-g DNA alone resulted
in the induction of CTL responses recognizing either autolo-
gous or allogeneic target cells or target cells infected with wild-
type vaccinia virus (Fig. 4c), suggesting that in vivo delivery of
the feline IFN-g plasmid may have stimulated a nonspecific
cellular immune response. No FIV-specific CTL activity was
observed in control cats inoculated with PBS alone (Fig. 4d).
Analysis of the CTL response 6 weeks after the initial im-
munization revealed a general decline in activity (Fig. 5). This
was most marked in the group coimmunized with FIVDRT
and IFN-g, in which no CTL activity could be detected. In the
FIVDRT-immunized group, although Gag- and Env-specific
CTL responses were still detectable in four of five cats, the lev-
els of lysis were lower than those observed at week 3. In two of
five cats (A481 and A482) in the FIVDRT group and three of
five cats (A487, A488, and A489) in the FIVDRT-plus-IFN-g-
coimmunized group, this activity remained at background lev-
els despite repeat inoculations of DNA. In contrast, a transient
boosting of FIV Gag-specific CTL activity was observed in the
remaining five cats at week 12, 2 weeks after the repeat DNA
inoculation administered at week 10, and in one animal (A490)
a transient increase in Env-specific CTL activity was observed
before the level declined to background levels (Fig. 6). Further
boosting at week 23 had a negligible effect on the FIV-specific
effector CTL responses detected in the peripheral blood (data
not shown), and all cats were challenged at week 26.
DNA immunization does not induce antiviral antibodies. In
contrast to the CTL responses, FIV-specific antibodies were
not detected by any available test, including ELISA for the
immunodominant TM peptide and immunoblot analysis with a
lysate of FIV-PET-infected cells (Table 1). Previous studies by
us and others have demonstrated these assays to be reliable
and sensitive measures of FIV-specific serological responses in
naturally infected cats (19, 39). Similarly, no virus-neutralizing
antibodies were detected in plasma samples taken on the day
of challenge.
FIVDRT vaccine affords protection against challenge with
infectious FIV. In view of the apparent refractory immune
state of the vaccinated cats, we decided to test their ability to
resist viral infection. All 20 cats were challenged at week 26
with the homologous FIV-PET isolate by intraperitoneal inoc-
ulation of 25 50% infectious doses. The cats were monitored
following challenge for the presence of infectious FIV and viral
DNA and for evidence of seroconversion.
Virus isolation was attempted at 0, 3, 6, 9, and 12 weeks
following challenge. Virus was isolated from 5 of 10 control
cats by week 3 postchallenge, as well as from 2 of 5 cats
inoculated with FIVDRT. In contrast, all of the cats inoculated
with FIVDRT plus IFN-g remained virus free at this time,
indicating that either their viral loads were below the detection
limit of the assay or infection was delayed in this group (Table
1). At 6, 9, and 12 weeks postchallenge, one of five FIVDRT
vaccinates and three of five FIVDRT-plus-IFN-g vaccinates
FIG. 2. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis of sedi-
mented virus particles released from FL4 cells persistently infected with FIV-
PET (lane1), mock-transfected CrFK cells (lane 2), CrFK cells transfected with
the F-14 molecular clone (lane 3), and CrFK cells transfected with the FIVDRT
construct (lane 4).
FIG. 3. Design of the two trials. Timings of immunizations and challenges (in
weeks) are represented by small and large arrows, respectively. CTL and sero-
logical assays were performed at the intervals denoted by the triangles and
symbols representing antibodies, respectively.
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remained virus free. In contrast, virus was isolated consistently
from all of the control cats (IFN-g alone and no-DNA control
groups) at 6, 9, and 12 weeks postchallenge.
Since all of the cats were seronegative on the day of chal-
lenge, positive immunoblot results and titers of antibodies rec-
ognizing the TM peptide indicated infection. The results of
serological tests confirmed previous observations that immu-
noblot analysis is the more sensitive indicator of infection in
cats infected with FIV-PET (18, 32), since not all of the in-
fected and immunoblot-positive cats developed detectable
titers of anti-FIV TM peptide antibodies by week 12 postchal-
lenge (Table 1). Furthermore, the immunoblot results corre-
lated closely with virus isolation results. Plasma from the four
cats which were virus isolation negative remained negative
throughout the experiment (Fig. 7). In contrast, the control
groups which received IFN-g alone or PBS all became sero-
positive by 6 weeks postchallenge (Table 1).
A total of five FIVDRT-vaccinated cats from which virus had
been isolated at both 6 and 9 weeks postchallenge became
negative at 12 weeks postchallenge, including two cats coin-
oculated with IFN-g DNA. These cats remained consistently
seropositive, confirming their infected status.
Reduced levels of virus and proviral DNA in peripheral
blood of FIVDRT vaccinates. Since there was evidence of lower
viral loads in the FIVDRT vaccinates, with inconsistent virus
isolation results and delayed seroconversion in some cats, we
measured the infectious-virus burdens in peripheral blood at 7
and 12 weeks postchallenge. Analysis of the results (Fig. 8a)
demonstrated that at week 7 there was a statistically significant
difference between the groups overall (F test, P 5 0.025).
However, none of the groups was statistically significantly dif-
ferent pairwise (two-sample t test, adjusted for multiple com-
parisons by permutation). When aggregated to the two groups
immunized with FIVDRT compared with the two control
groups, the FIVDRT vaccinates had a statistically significantly
lower log initial number of infected cells per 2 3 106 PBMC
FIG. 4. FIV Gag- and Env-specific effector CTL responses were measured directly on the fresh PBMC collected from vaccinated (FIVDRT [a]; FIVDRT plus IFN-g
[b]) and control (IFN-g [c]; PBS alone [d]) cats in trial 1, 3 weeks after the first immunization. Autologous or allogeneic skin fibroblasts infected with recombinant
vaccinia viruses expressing either FIV Gag (10) (n and u) or FIV Env (41) (o and ^) or wild-type vaccinia virus (h) were labelled with 51Cr and used as targets in
the assay. The release of 51Cr into the culture supernatant was detected after 4 h of incubation at 37°C. The results shown represent the mean values for triplicate
cultures at an E/T ratio of 50:1.
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than did the controls (Fig. 8a). At week 12, pairwise contrasts
between vaccinated and control groups were all statistically
significant, with P , 0.02 (i.e., FIVDRT compared to IFN-g,
FIVDRT compared to no DNA, FIVDRT plus IFN-g com-
pared to IFN-g, and FIVDRT plus IFN-g compared to no DNA).
Similar conclusions emerged from quantitative PCR analysis
of proviral DNA in PBMC. The results shown in Table 2
represent the results obtained with the env primers, and these
correlated closely with parallel assays involving pol primers
(data not shown). Although the levels of proviral DNA were
low in the control cats following challenge with the F-14 mo-
lecular clone, these findings were broadly consistent with our
earlier study of cats infected with a low dose of the FIV-PET
isolate (32). Despite the low overall levels of DNA and evi-
dence of declining load from weeks 6 to 12, clear differences
among the four vaccine groups were evident. All of the control
cats immunized with either IFN-g or no DNA scored positive
in PCRs with 250 ng of DNA at 6 weeks, compared to only 4
of 10 FIVDRT vaccinates. By 12 weeks postchallenge, only 6 of
10 control cats yielded positive results from 500 ng of DNA
compared to 10 of 10 at week 6, indicating that the proviral
loads later in infection are decreased. The four cats which
remained negative by virus isolation and seronegative by im-
munoblotting and ELISA gave isolated, transient positive PCR
results, three at 6 weeks postinfection and one at 12 weeks.
These results indicate that the proviral loads in these cats are
close to the detection limit of the assay. Of the remaining six
vaccinates, all of which yielded positive results by virus isola-
tion and immunoblotting, a single cat was uniformly negative
by PCR, three gave single positive PCR results at week 6 post-
challenge, one gave positive results at high DNA concentra-
tions at weeks 6 and 12, and the remaining cat gave positive
PCR results at all DNA concentrations tested. It was notable
that all of the cats in the group which received FIVDRT and
IFN-g became uniformly negative by PCR by 12 weeks post-
challenge even at the highest input of 1 mg of DNA.
The FIVDRT immunization schedule can be reduced with-
out apparent loss of efficacy. To investigate whether the lengthy
immunization schedule could be reduced without compromis-
ing protection, we conducted a second experiment in which two
groups of five cats received either FIVDRT plus IFN-g or IFN-
g alone at 0, 4, and 8 weeks. As in the first trial, this regimen
FIG. 5. Detection of FIV Gag- and Env-specific CTL responses directly in fresh PBMC collected from vaccinated (FIVDRT [a]; FIVDRT plus IFN-g [b]) and
control (IFN-g [c]; PBS alone [d]) cats in trial 1, 6 weeks after the first immunization. Autologous or allogeneic target cell express either FIV Gag (n and u) or FIV
Env (o and ^) or no FIV proteins (infected with wild-type vaccinia virus [h]). The results shown represent the mean 51Cr release after a 4-h incubation at 37°C for
triplicate cultures at an E/T ratio of 50:1.
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induced cytolytic activity (data not shown) but no detectable
antibody responses by the same series of assays (immunofluo-
rescence, immunoblotting, anti-TM peptide ELISA, and assay
for virus-neutralizing antibodies). After challenge at 12 weeks,
two of five vaccinates remained seronegative and virus could
not be isolated at any of the times tested (Table 1) whereas all
of the IFN-g-alone controls became seropositive and positive
by virus isolation, consistent with the results of the first trial.
Again, immunoblot analysis corroborated these findings (Fig.
7b). Quantitative measurements of virus in the second trial (Fig.
8b) revealed that at 6 weeks postchallenge, the FIVDRT-plus-
IFN-g vaccinates developed significantly lower viral loads than
did the IFN-g vaccinates (P 5 0.027). By 9 weeks postchal-
lenge, the viral loads of all of the cats were low and there were
no differences between the groups (data not shown).
DISCUSSION
This study demonstrates that protection against FIV infec-
tion can be achieved by intramuscular administration of non-
replicating FIV DNA. A significant proportion of FIVDRT
vaccinates was protected, and the mean viral loads of the
vaccinates were significantly reduced compared to those of
the control cats. Similar results were obtained in a second trial
in which the immunization schedule was shorter, indicating
that the interval between immunizations did not appear to
influence the protected status of vaccinated cats.
The mechanism of protection is of great interest, particularly
in view of the lack of a detectable humoral immune response
in the vaccinates prior to challenge. Our results provide an in-
triguing parallel with the apparently protected status of indi-
viduals exposed to HIV who remain seronegative but have
measurable CTL responses (35, 37), suggesting that a potent
cellular immune response may be sufficient to confer immunity
to infection. The induction of CTL in the absence of a detect-
able humoral immune response following immunization with
the FIVDRT DNA vaccine is in contrast to the responses
observed recently following immunization of chimpanzees with
a prospective HIV DNA vaccine (4). Following immunization
with a plasmid carrying HIV env and rev under the regulatory
control of the cytomegalovirus promoter, antibodies specific
FIG. 6. Detection of FIV Gag- and Env-specific CTL responses directly in fresh PBMC collected from vaccinated (FIVDRT [a]; FIVDRT plus IFN-g [b]) and
control (IFN-g [c]; PBS alone [d]) cats in trial 1, 1 week after the second immunization. Autologous or allogeneic target cells express either FIV Gag (n and 1) or
FIV Env (o and ^) or no FIV proteins (infected with wild-type vaccinia virus [h]). The results shown represent the mean 51Cr release after a 4-h incubation at 37°C
for triplicate cultures at an E/T ratio of 50:1. ND, not done.
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for HIV Env were detected in all four immunized animals (4).
However, it is notable that even with the protracted immuni-
zation regime used to immunize the chimpanzees, there were
marked differences in the titers of antibodies induced following
immunization. Moreover, three of the four immunized chim-
panzees failed to generate a humoral response to the viral Gag
protein. In this study, we were unable to detect antibodies
specific for either FIV Env or Gag proteins in the cats immu-
nized with either FIVDRT alone or FIVDRT in conjunction
with IFN-g. In agreement with our findings, a recent study in-
volving FIV env gene-based DNA vaccines induced either low
or undetectable levels of FIV-specific antibodies (31).
The bias toward CTL induction rather than antibody pro-
duction in response to inoculation with FIVDRT suggested
that intramuscular administration of the FIVDRT DNA gen-
erated primarily a Th1-type immune response. Given that pre-
vious studies have demonstrated that it is possible to generate
potent cellular and humoral immune responses following im-
munization of macaques with plasmids expressing the env and
gag genes of SIVmac251 (24, 34, 49), there is clearly scope for
further optimization of the vaccination schedule. However, the
question is then which type of immune response is likely to
confer protective immunity to challenge with a lentivirus. The
SIVmac251-based DNA vaccine neither protected the immu-
nized macaques from challenge with the homologous virus nor
led to a reduction in the viral load of the vaccinates (24). Sig-
nificantly, the SIVmac251 challenge is a highly pathogenic vi-
rus; recent data suggest that the FIV-PET challenge virus used
in our study is less pathogenic than the FIV GL-8 strain (21).
Similarly, the HIV-1 SF2 challenge virus used in the chimpan-
zee DNA vaccine trial does not induce disease readily in in-
fected animals (4). Future studies should address whether pro-
tective immunity to infection with highly pathogenic strains of
FIV (7) can be achieved with DNA vaccines.
CTL activity to FIV Env was shown previously to correlate
with long-lived immunity induced by whole inactivated virus
vaccines (11). In the present study, there was no clear corre-
lation between the elicitation of Env- or Gag-specific CTL
responses in the peripheral blood of vaccinated cats and the
protection observed following challenge, since qualitatively
similar CTL responses were detected in both protected and
unprotected cats within each vaccine group. Future studies will
TABLE 1. Titers of antibody responses to FIV TM peptide, reactivity of plasma samples by immunoblotting, and results of
virus isolation on the day of challenge and at intervals following challenge
DNA
inoculum Cat
Antibody responsea at time (wk) postchallenge:
0 3 6 9 12
IB VI TM IB VI IB VI IB VI IB VI TM
Trial 1
FIVDRT 1 2 2 0 2 2 2 1 1 1 2 0
2 2 2 0 2 1 2 1 1 1 1 2 0
3 2 2 0 2 2 2 1 1 1 1 1 0
4 2 2 0 2 2 2 2 2 2 2 2 0
5 2 2 0 2 1 1 1 1 1 1 2 25
FIVDRT 1 IFN-g 1 2 2 0 2 2 2 2 2 2 2 2 0
2 2 2 0 2 2 1 1 1 1 1 2 0
3 2 2 0 2 2 2 2 2 2 2 2 0
4 2 2 0 2 2 1 1 1 1 1 2 125
5 2 2 0 2 2 2 2 2 2 2 2 0
IFN-g 1 2 2 0 2 1 1 1 1 1 1 1 125
2 2 2 0 2 1 1 1 1 1 1 2 25
3 2 2 0 2 2 1 1 1 1 1 1 25
4 2 2 0 2 2 1 1 1 1 1 1 25
5 2 2 0 2 1 1 1 1 1 1 1 5
No DNA 1 2 2 0 2 2 1 1 1 1 1 1 25
2 2 2 0 2 1 1 1 1 1 1 1 5
3 2 2 0 2 2 1 1 1 1 1 1 5
4 2 2 0 2 2 1 1 1 1 1 1 125
5 2 2 0 2 1 1 1 1 1 1 1 5
Trial 2
FIVDRT 1 IFN-g 1 2 2 0 ND 1 1 1 ND 1 1 1 25
2 2 2 0 ND 2 2 2 ND 2 2 2 0
3 2 2 0 ND 2 2 1 ND 1 1 2 0
4 2 2 0 ND 1 1 1 ND 1 1 2 25
5 2 2 0 ND 2 2 2 ND 2 2 2 0
IFN-g 1 2 2 0 ND 1 1 1 ND 1 1 1 25
2 2 2 0 ND 1 1 1 ND 1 1 2 125
3 2 2 0 ND 1 2 1 ND 1 1 1 5
4 2 2 0 ND 2 2 1 ND 1 1 1 25
5 2 2 0 ND 2 2 1 ND 1 1 1 25
a IB, immunoblotting; VI, virus isolation; TM, titer of antibodies recognizing TM peptide; ND, not done.
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address the contribution of CTL responses with other viral
specificities in protective immunity and will investigate the
sequestration of virus-specific CTLs to the lymphoid organs,
which may explain the rather short-lived CTL responses ob-
served in the peripheral blood. It should now be possible to
identify the critical targets for the protective immune response
by selective gene inactivation. Given that immunization of cats
with FIV env gene-based DNA vaccines resulted in enhance-
ment of infection following challenge (31), it is possible that
regulatory gene products expressed by the FIVDRT DNA vac-
cine contributed to its greater efficacy.
A greater proportion of the cats in the group inoculated with
IFN-g in conjunction with FIVDRT was protected following
challenge compared to the proportion in the group inoculated
with FIVDRT alone, suggesting that IFN-g may have enhanced
the protective effect of FIVDRT. IFN-g is a pleiotropic im-
mune regulator which is depressed in progressive HIV infec-
FIG. 7. Immunoblot analysis performed as described previously (19) on plasma samples taken from cats 12 weeks after challenge. (a) Trial 1 (numbered lanes) and
plasma from an FIV-infected and an unvaccinated, uninfected cat as controls (lanes 1 and 2, respectively). One cat in the group immunized with DRT (lane 4) and
three cats in the group immunized with DRT and IFN-g (lanes 1, 3, and 5) remained antibody negative after challenge. (b) Trial 2 (numbered lanes) and control lanes
as in panel a. Two cats (lanes 2 and 4) immunized with DRT and IFN-g remained antibody negative after challenge.
FIG. 8. Viral loads in trial 1 at 7 weeks postchallenge (a) and in trial 2 at 6
weeks postchallenge (b), expressed as the mean 6 2 standard errors of the mean
of the log-transformed maximum-likelihood estimates of the initial number of
infected cells present in 2 3 106 PBMC.
TABLE 2. Comparison of viral loads in trial 1 at 6 and 12 weeks
postchallenge as measured by quantitative nested PCR
DNA
inoculum Cat
PCR result
(wk 6)a
PCR result
(wk 12)a Serocon-
version
500 ng 250 ng 1,000 ng 500 ng 250 ng
FIVDRT 1 1 2 2 2 2 1
2 2 2 2 2 2 1
3 1 2 1 2 2 1
4 2 2 2 1 2 2
5 1 1 2 1 1 1
FIVDRT 1
IFN-g
1 1 2 2 2 2 2
2 2 1 2 2 2 1
3 1 2 2 2 2 2
4 2 1 2 2 2 1
5 NDb 1 2 2 2 2
IFN-g 1 1 1 1 1 2 1
2 1 1 1 2 2 1
3 1 1 1 2 1 1
4 1 1 2 2 2 1
5 1 1 1 2 2 1
No DNA 1 1 1 1 1 1 1
2 1 1 1 1 1 1
3 1 1 2 1 1 1
4 1 1 2 1 1 1
5 1 1 1 1 1 1
a Positive scores denote a positive amplification in one or more aliquots.
Serological responses were determined 12 weeks after challenge by immunoblot-
ting, as shown in Fig. 7.
b ND, not done.
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tion and has been reported to be inversely correlated with
lymph node virus load in primary SIV infection of macaques
(23). Although recombinant IFN-g is being investigated widely
as a therapeutic agent (15), its use as a gene adjuvant has been
limited so far. Interestingly, replacement of the nef gene in
infectious SIVmac with a human IFN-g gene was recently
found to cause further attenuation of the virus and to enhance
protection against superinfection with virulent virus (14).
Whether these effects are mediated by specific or nonspecific
immune mechanisms remains to be determined.
Our results raise wider questions about the role of antibod-
ies in natural and vaccinal immunity to lentiviruses. Hitherto,
our assumption has been that vaccines should stimulate the
broadest possible range of effector mechanisms, and our pre-
vious studies with whole inactivated FIV vaccines demon-
strated that neutralizing antibodies correlated with protection
(16). However, previous studies have described enhancement
of FIV infection following immunization with prospective vac-
cines, including subunit vaccines and a DNA vaccine express-
ing a limited range of FIV gene products (20, 31, 40). Further
studies are necessary to account for the different outcomes of
these vaccine experiments compared to the present study and
to allow extrapolation of these findings to other immunosup-
pressive lentiviruses such as HIV in human beings.
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